Dr. Christiane Smerling, 3B Pharmaceuticals GmbH
"...I particularly appreciate Trenzyme's scientific competence and their proactive communication during our collaboration, and I certainly hope that we will continue this collaboration in the years to come..."
Oxford Expression Technologies Ltd (OET) and Trenzyme GmbH, both experts in the field of recombinant protein expression have agreed to collaborate so that the full potential of their complementary technologies can be realized.
Under terms of the collaboration, both companies will be able to offer a full range of recombinant protein expression services across a variety of platforms including baculovirus, yeast, bacterial and mammalian systems.
The collaboration offers exciting possibilities in the field of the rapidly developing BacMam system, in which baculoviruses are used for protein production in mammalian cell lines. The BacMam system increases the options available to improve both the yield and quality of recombinant proteins. It also has applications in therapeutic fields including the production of recombinant vaccines and gene delivery into human cells.
Furthermore, the BacMam system fits perfectly to the Cross Organism Expression platform of Trenzyme allowing the fast and reliable screening of the best expression host for a given target protein in respect of timelines, yield and quality.
Since 2009 Trenzyme has a licensing agreement with Cytobox for Trenzyme's validated ExoIN technology. The ExoIN technology allows Cytobox to offer validated homogenous stable mammalian cell line gerenation in just 30 business days.
AAC Infotray is our trusted partner providing us with customized RALIMS and BPM software solutions.
Naturblau+++ Konstanz, our partner for corporate design.
Genaxxon, our partner for life science products and consumables.